[2] [2] GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990- 2019: a systematic analysis for the Global Burden of Disease Study 2019［J］. Lancet, 2020, 396(10258): 1204-1222.

[3] [3] PERONT S, TERME M, VORON T, et al. Colorectal cancer and immunity: what we know and perspectives［J］.?World Journal of Gastroenterol, 2014, 20(14): 3738-3750.

[5] [5] CROSBY E J, GWIN W, BLACKWALL K, et al. Vaccine-induced memory CD8+ T cells provide clinical benefit in her2 expressing breast cancer: a mouse to human translational study［J］.?Clinical Cancer Research, 2019, 25(9): 2725-2736.?

[6] [6] MIYAZAWA M, OHSAWA R, TSUNODA T, et al. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer［J］. Cancer Science, 2010, 101: 433-439.

[7] [7] HASEGAWA K, IKEDA Y, KUNUGI Y, et al. Phase I study of multiple epitope peptide vaccination in patients with recurrent or persistent cervical cancer［J］. Journal of Immunother, 2018, 41(4): 201-207.

[8] [8] SAHIN U, DERHOVANESSIAN E, MILLER M, et al. Person-alized RNA mutanome vaccines mobilize poly-specific therapeu-tic immunity against cancer［J］. Nature, 2017, 547(7662): 222-226.

[9] [9] GARCIA-MUNOZ R, LOPEZ-DIAZ-DE-CERIO A, FELIU J, et al. Follicular lymphoma: in vitro effects of combining lympho-kine-activated killer (LAK) cell-induced cytotoxicity and ritux-imab-and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity［J］. Immunologic Research, 2016, 64(2): 548-557.

[10] [10] CLARK K L, HALAY E D, LAI E, et al. Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5［J］.?Nature, 1993, 364(6436): 412-420.

[11] [11] RAYCHAUDHURI P, PARK H J. FoxM1: a master regulator of tumor metastasis［J］. Cancer Research, 2011, 71(13): 4329-4333.

[12] [12] CHAN D W, YU S Y, CHIU P M, et a1. Over-expression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesis［J］. The Journal of Pathology, 2008, 215(3): 245-252．

[13] [13] ZENG J, WANG L , LI Q, et a1. FoxMl is up-regulated in gastric cancer and its inhibition leads to cellular senescence, partially dependent on p27［J］. The Journal of Pathology, 2009, 218(4): 419- 427．

[14] [14] CHANDRAN U R, MA C, DHIR R, et a1. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process reveal［J］. BMC Cancer, 2007, 12(7): 64．

[15] [15] ZHANG Z, BU H, YU J, et al. The cell-penetrating FOXM1 N-terminus (M1-138) demonstrates potent inhibitory effects on cancer cells by targeting FOXM1 and FOXM1-interacting factor SMAD3［J］.?Theranostics, 2019, 9(10): 2882-2896.

[16] [16] HEYER B S, WARSOWE J, SOLTER D, et al. New member of the Snf1/AMPK kinase family, Melk, is expressed in the mouse egg and preimplantation embryo［J］. Molecular Reproduction and Development, 1997, 47(2): 148-156.

[17] [17] KATO T, SATO N, HAYAMA S, et al. Activation of holliday junction recognizing protein involved in the chromosomal stability and immortality of cancer cells［J］. Cancer Research, 2007, 67: 8544-8553.

[20] [20] BROWNE G, TAIPALEENMAKI H, BISHOP N M, et al. Runx1 is associated with breast cancer progression in MMTV-PyMT transgenic mice and its depletion in vitro inhibits migration and invasion［J］. Journal of Cellular Physiology, 2015, 230(10): 2522-2532.

[21] [21] TARDON M C, ALLARD M, DUTOIT V, et al. Peptides as cancer vaccines［J］. Current Opinion Pharmacology, 2019, 47: 20-26

[22] [22] SLINGLUFF C L Jr. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?［J］.?Cancer Journal, 2011, 17(5): 343-350.

[23] [23] ZHOU J, ZOU Y, CAI Y, et al. A designed cyclic peptide based on Trastuzumab used to construct peptide-drug conjugates for its HER2-targeting ability［J］.?Bioorganic Chemistry, 2021, 117: 105453.